BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Lancelot E. Revisiting the Pharmacokinetic Profiles of Gadolinium-Based Contrast Agents: Differences in Long-Term Biodistribution and Excretion. Invest Radiol 2016;51:691-700. [DOI: 10.1097/rli.0000000000000280] [Cited by in Crossref: 62] [Cited by in F6Publishing: 18] [Article Influence: 10.3] [Reference Citation Analysis]
Number Citing Articles
1 Scala M, Koob M, de Buttet S, Bourrinet P, Felices M, Jurkiewicz E. A Pharmacokinetics, Efficacy, and Safety Study of Gadoterate Meglumine in Pediatric Subjects Aged Younger Than 2 Years. Invest Radiol 2018;53:70-9. [PMID: 28906338 DOI: 10.1097/RLI.0000000000000412] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
2 Fretellier N, Granottier A, Rasschaert M, Grindel AL, Baudimont F, Robert P, Idée JM, Corot C. Does Age Interfere With Gadolinium Toxicity and Presence in Brain and Bone Tissues?: A Comparative Gadoterate Versus Gadodiamide Study in Juvenile and Adult Rats. Invest Radiol 2019;54:61-71. [PMID: 30394964 DOI: 10.1097/RLI.0000000000000517] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 4.7] [Reference Citation Analysis]
3 de Boer A, Harteveld AA, Pieters TT, Blankestijn PJ, Bos C, Froeling M, Joles JA, Verhaar MC, Leiner T, Hoogduin H. Decreased native renal T1 up to one week after gadobutrol administration in healthy volunteers. J Magn Reson Imaging 2020;52:622-31. [PMID: 31799793 DOI: 10.1002/jmri.27014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
4 Davies J, Siebenhandl-Wolff P, Tranquart F, Jones P, Evans P. Gadolinium: pharmacokinetics and toxicity in humans and laboratory animals following contrast agent administration. Arch Toxicol 2022. [PMID: 34997254 DOI: 10.1007/s00204-021-03189-8] [Reference Citation Analysis]
5 Goetzl EJ, Maecker HT, Rosenberg-hasson Y, Koran LM. Altered Functional Mitochondrial Protein Levels in Plasma Neuron-Derived Extracellular Vesicles of Patients With Gadolinium Deposition. Front Toxicol 2022;3:797496. [DOI: 10.3389/ftox.2021.797496] [Reference Citation Analysis]
6 Ognard J, Barrat JA, Cotton F, Mian A, Kremer S, Sitoh YY, Verclytte S, Loffroy R, Tripier R, Alavi Z, Ben Salem D. A roadmap towards pollution prevention and sustainable development of Gadolinium. J Neuroradiol 2021;48:409-11. [PMID: 34506855 DOI: 10.1016/j.neurad.2021.08.002] [Reference Citation Analysis]
7 Imran M, Ramzan M, Qureshi AK, Khan MA, Tariq M. Emerging Applications of Porphyrins and Metalloporphyrins in Biomedicine and Diagnostic Magnetic Resonance Imaging. Biosensors (Basel) 2018;8:E95. [PMID: 30347683 DOI: 10.3390/bios8040095] [Cited by in Crossref: 63] [Cited by in F6Publishing: 24] [Article Influence: 15.8] [Reference Citation Analysis]
8 Chubb H, Aziz S, Karim R, Sohns C, Razeghi O, Williams SE, Whitaker J, Harrison J, Chiribiri A, Schaeffter T, Wright M, O'Neill M, Razavi R. Optimization of late gadolinium enhancement cardiovascular magnetic resonance imaging of post-ablation atrial scar: a cross-over study. J Cardiovasc Magn Reson 2018;20:30. [PMID: 29720202 DOI: 10.1186/s12968-018-0449-8] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
9 Schieda N, Blaichman JI, Costa AF, Glikstein R, Hurrell C, James M, Jabehdar Maralani P, Shabana W, Tang A, Tsampalieros A, van der Pol CB, Hiremath S. Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018;5:2054358118778573. [PMID: 29977584 DOI: 10.1177/2054358118778573] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 9.3] [Reference Citation Analysis]
10 Finn JP. Editorial for "Decreased Native Renal T1 Up to One Week After Gadobutrol Administration in Healthy Volunteers". J Magn Reson Imaging 2020;52:632-3. [PMID: 32558035 DOI: 10.1002/jmri.27262] [Reference Citation Analysis]
11 Amin R, Darrah T, Wang H, Amin S. Editor's Highlight: In Utero Exposure to Gadolinium and Adverse Neonatal Outcomes in Premature Infants. Toxicol Sci 2017;156:520-6. [PMID: 28201627 DOI: 10.1093/toxsci/kfx013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
12 Shahid I, Joseph A, Lancelot E. Use of Real-Life Safety Data From International Pharmacovigilance Databases to Assess the Importance of Symptoms Associated With Gadolinium Exposure. Invest Radiol 2022. [PMID: 35471204 DOI: 10.1097/RLI.0000000000000880] [Reference Citation Analysis]
13 Young LK, Matthew SZ, Houston JG. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals. Eur Radiol 2019;29:1922-30. [PMID: 30276674 DOI: 10.1007/s00330-018-5737-z] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 van der Molen AJ. Gadolinium Deposition in the Brain and Body. Journal of the Belgian Society of Radiology 2019;103:71. [DOI: 10.5334/jbsr.1945] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Rasschaert M, Idée JM, Robert P, Fretellier N, Vives V, Violas X, Ballet S, Corot C. Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats. Invest Radiol 2017;52:255-64. [PMID: 28067754 DOI: 10.1097/RLI.0000000000000339] [Cited by in Crossref: 35] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]
16 Lohrke J, Frisk AL, Frenzel T, Schöckel L, Rosenbruch M, Jost G, Lenhard DC, Sieber MA, Nischwitz V, Küppers A, Pietsch H. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents. Invest Radiol 2017;52:324-33. [PMID: 28323657 DOI: 10.1097/RLI.0000000000000344] [Cited by in Crossref: 105] [Cited by in F6Publishing: 44] [Article Influence: 26.3] [Reference Citation Analysis]
17 Rees JA, Deblonde GJ, An DD, Ansoborlo C, Gauny SS, Abergel RJ. Evaluating the potential of chelation therapy to prevent and treat gadolinium deposition from MRI contrast agents. Sci Rep 2018;8:4419. [PMID: 29535330 DOI: 10.1038/s41598-018-22511-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
18 Fathi A, Weir-McCall JR, Struthers AD, Lipworth BJ, Houston G. Effects of contrast administration on cardiac MRI volumetric, flow and pulse wave velocity quantification using manual and software-based analysis. Br J Radiol 2018;91:20170717. [PMID: 29271236 DOI: 10.1259/bjr.20170717] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Prybylski JP, Jay M. The Impact of Excess Ligand on the Retention of Nonionic, Linear Gadolinium-Based Contrast Agents in Patients With Various Levels of Renal Dysfunction: A Review and Simulation Analysis. Adv Chronic Kidney Dis 2017;24:176-82. [PMID: 28501081 DOI: 10.1053/j.ackd.2017.03.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
20 Boyken J, Frenzel T, Lohrke J, Jost G, Schütz G, Pietsch H. Impact of Treatment With Chelating Agents Depends on the Stability of Administered GBCAs: A Comparative Study in Rats. Invest Radiol 2019;54:76-82. [PMID: 30358694 DOI: 10.1097/RLI.0000000000000522] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
21 Alwasiyah D, Murphy C, Jannetto P, Hogg M, Beuhler MC. Urinary Gadolinium Levels After Contrast-Enhanced MRI in Individuals with Normal Renal Function: a Pilot Study. J Med Toxicol 2019;15:121-7. [PMID: 30543028 DOI: 10.1007/s13181-018-0693-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
22 Robert P, Frenzel T, Factor C, Jost G, Rasschaert M, Schuetz G, Fretellier N, Boyken J, Idée JM, Pietsch H. Methodological Aspects for Preclinical Evaluation of Gadolinium Presence in Brain Tissue: Critical Appraisal and Suggestions for Harmonization-A Joint Initiative. Invest Radiol 2018;53:499-517. [PMID: 29659381 DOI: 10.1097/RLI.0000000000000467] [Cited by in Crossref: 30] [Cited by in F6Publishing: 10] [Article Influence: 10.0] [Reference Citation Analysis]
23 Splendiani A, Perri M, Marsecano C, Vellucci V, Michelini G, Barile A, Di Cesare E. Effects of serial macrocyclic-based contrast materials gadoterate meglumine and gadobutrol administrations on gadolinium-related dentate nuclei signal increases in unenhanced T1-weighted brain: a retrospective study in 158 multiple sclerosis (MS) patients. Radiol Med 2018;123:125-34. [PMID: 28952018 DOI: 10.1007/s11547-017-0816-9] [Cited by in Crossref: 35] [Cited by in F6Publishing: 39] [Article Influence: 7.0] [Reference Citation Analysis]
24 Mijnders LS, Steup FW, Lindhout M, van der Kleij PA, Brink WM, van der Molen AJ. Optimal sequences and sequence parameters for GBCA-enhanced MRI of the glymphatic system: a systematic literature review. Acta Radiol 2021;62:1324-32. [PMID: 33153270 DOI: 10.1177/0284185120969950] [Reference Citation Analysis]
25 McDonald RJ, Levine D, Weinreb J, Kanal E, Davenport MS, Ellis JH, Jacobs PM, Lenkinski RE, Maravilla KR, Prince MR, Rowley HA, Tweedle MF, Kressel HY. Gadolinium Retention: A Research Roadmap from the 2018 NIH/ACR/RSNA Workshop on Gadolinium Chelates. Radiology 2018;289:517-34. [PMID: 30204075 DOI: 10.1148/radiol.2018181151] [Cited by in Crossref: 121] [Cited by in F6Publishing: 93] [Article Influence: 30.3] [Reference Citation Analysis]